A blood marker may reveal how well diabetes treatments are working

NCT ID NCT07734558

Not yet recruiting Knowledge-focused Sponsor: GÜLDEN ANATACA Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This study looks at whether levels of a protein called Neuregulin-4 (NRG4) in the blood are linked to obesity, insulin resistance, and different diabetes treatments in people with type 2 diabetes. Researchers will compare NRG4 levels across groups including obese and non-obese patients on various medications, newly diagnosed patients, and healthy controls. The goal is to see if NRG4 could serve as a simple biomarker for metabolic health and treatment response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If NRG4 levels reliably reflect metabolic status, it could become a simple blood test to help guide diabetes treatment.
What could go wrong: This is an observational study, not a treatment trial. It can only show associations, not cause and effect. The findings may not lead to a practical test.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Insulin Resistance Obesity type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INSULIN RESISTANCE OBESITY TYPE 2 DIABETES MELLITUS TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Locations

Kanuni Sultan Süleyman Training and Research Hospital

Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.